Jean-Maurice Dumont

TL;DR: DBIO‐025, a compound that is also endowed with potent anti‐HIV activity and is well tolerated in animals and humans, may form an attractive new option for the therapy of HCV infections, particularly in HCV/HIV co‐infected patients.

TL;DR: Two new nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 are evaluated for their ability to inhibit mPT in rat brain-derived mitochondria and will be instrumental in the evaluation of mPT as a central target for neuroprotection in vivo.

TL;DR: It is demonstrated that DEBIO‐025 was better tolerated than CsA, and that its anti‐HCV effect appeared to be synergistic in combination with Peg‐IFN in vivo.

TL;DR: This study demonstrates that specific capsid substitutions can release HIV-1 from both CypA dependence in human cells and TRIM-Cyp restriction in monkey cells.

TL;DR: By interfering at the level of host–viral interaction, Cyp inhibition may open the way for a novel approach to anti-HCV treatment that could be complementary, not only to interferon-based treatment, but also to future treatments that directly target HCV replication enzymes such as protease and polymerase inhibitors.